# Retractable Technologies Inc: financial statements, quarterly

RVP · NYSE · CIK 946563 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/rvp.md) · [Financials](/companies/rvp/financials.md) · [Filings](/companies/rvp/filings.md) · [Insiders](/companies/rvp/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/rvp/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [10.3](/filings/0001558370-24-015682.md) | [14.3 d](/filings/0001104659-26-036053.md) | [7.6](/filings/0001558370-25-007853.md) | [6.0](/filings/0001558370-25-011539.md) | [10.3](/filings/0001104659-25-112205.md) | [9.1 d](/filings/0001104659-26-036053.md) | [8.3](/filings/0001104659-26-062253.md) | [10.4](/filings/0001104659-26-097216.md) | [10.1](/filings/0001104659-25-112205.md) | [9.4 d](/filings/0001104659-26-036053.md) | [7.2](/filings/0001104659-26-062253.md) | [7.2](/filings/0001104659-26-097216.md) |
| Cost of revenue | $m | [6.0](/filings/0001558370-24-015682.md) | [12.7 d](/filings/0001104659-26-036053.md) | [5.7](/filings/0001558370-25-007853.md) | [6.4](/filings/0001558370-25-011539.md) | [10.4](/filings/0001104659-25-112205.md) | [11.6 d](/filings/0001104659-26-036053.md) | [8.3](/filings/0001104659-26-062253.md) | [10.6](/filings/0001104659-26-097216.md) | [8.4](/filings/0001104659-25-112205.md) | [11.0 d](/filings/0001104659-26-036053.md) | [8.0](/filings/0001104659-26-062253.md) | [7.0](/filings/0001104659-26-097216.md) |
| Gross profit | $m | [4.3](/filings/0001558370-24-015682.md) | [1.5 d](/filings/0001104659-26-036053.md) | [1.9](/filings/0001558370-25-007853.md) | [(0.4)](/filings/0001558370-25-011539.md) | [(0.0)](/filings/0001104659-25-112205.md) | [(2.5) d](/filings/0001104659-26-036053.md) | [(0.0)](/filings/0001104659-26-062253.md) | [(0.1)](/filings/0001104659-26-097216.md) | [1.7](/filings/0001104659-25-112205.md) | [(1.5) d](/filings/0001104659-26-036053.md) | [(0.8)](/filings/0001104659-26-062253.md) | [0.2](/filings/0001104659-26-097216.md) |
| Research and development | $m | [0.2](/filings/0001558370-24-015682.md) | [0.2 d](/filings/0001104659-26-036053.md) | [0.1](/filings/0001558370-25-007853.md) | [0.2](/filings/0001558370-25-011539.md) | [0.2](/filings/0001104659-25-112205.md) | [0.2 d](/filings/0001104659-26-036053.md) | [0.2](/filings/0001104659-26-062253.md) | [0.2](/filings/0001104659-26-097216.md) | [0.2](/filings/0001104659-25-112205.md) | [0.1 d](/filings/0001104659-26-036053.md) | [0.2](/filings/0001104659-26-062253.md) | [0.2](/filings/0001104659-26-097216.md) |
| Operating income | $m | [(0.9)](/filings/0001558370-24-015682.md) | [(2.8) d](/filings/0001104659-26-036053.md) | [(3.0)](/filings/0001558370-25-007853.md) | [(5.8)](/filings/0001558370-25-011539.md) | [(5.1)](/filings/0001104659-25-112205.md) | [(7.2) d](/filings/0001104659-26-036053.md) | [(4.7)](/filings/0001104659-26-062253.md) | [(5.1)](/filings/0001104659-26-097216.md) | [(3.7)](/filings/0001104659-25-112205.md) | [(7.7) d](/filings/0001104659-26-036053.md) | [(6.2)](/filings/0001104659-26-062253.md) | [(5.1)](/filings/0001104659-26-097216.md) |
| Interest expense | $m | [0.0](/filings/0001558370-23-018960.md) | [0.0 d](/filings/0001558370-24-004361.md) | [0.0](/filings/0001558370-24-008277.md) | [0.0](/filings/0001558370-25-011539.md) | [0.0](/filings/0001104659-25-112205.md) | [0.0 d](/filings/0001104659-26-036053.md) | [0.0](/filings/0001104659-26-062253.md) | [0.0](/filings/0001104659-26-097216.md) | [0.0](/filings/0001104659-25-112205.md) | [0.0 d](/filings/0001104659-26-036053.md) | [0.0](/filings/0001104659-26-062253.md) | [0.0](/filings/0001104659-26-097216.md) |
| Income tax | $m | [(1.2)](/filings/0001558370-24-015682.md) | [0.0 d](/filings/0001104659-26-036053.md) | [0.1](/filings/0001558370-25-007853.md) | [8.3](/filings/0001558370-25-011539.md) | [(0.0)](/filings/0001104659-25-112205.md) | [0.0 d](/filings/0001104659-26-036053.md) | [0.3](/filings/0001104659-26-062253.md) | [0.0](/filings/0001104659-26-097216.md) | [0.0](/filings/0001104659-25-112205.md) | [0.0 d](/filings/0001104659-26-036053.md) | [0.0](/filings/0001104659-26-062253.md) | [0.0](/filings/0001104659-26-097216.md) |
| Net income | $m | [(4.1)](/filings/0001558370-24-015682.md) | [(0.1) d](/filings/0001104659-26-036053.md) | [0.4](/filings/0001558370-25-007853.md) | [(14.2)](/filings/0001558370-25-011539.md) | [(1.9)](/filings/0001104659-25-112205.md) | [3.8 d](/filings/0001104659-26-036053.md) | [(10.5)](/filings/0001104659-26-062253.md) | [(0.1)](/filings/0001104659-26-097216.md) | [0.4](/filings/0001104659-25-112205.md) | [(2.3) d](/filings/0001104659-26-036053.md) | [(4.2)](/filings/0001104659-26-062253.md) | [2.8](/filings/0001104659-26-097216.md) |
| Diluted EPS | $ per share | [(0.14)](/filings/0001558370-24-015682.md) | not reported | [0.01](/filings/0001558370-25-007853.md) | [(0.48)](/filings/0001558370-25-011539.md) | [(0.07)](/filings/0001104659-25-112205.md) | not reported | [(0.35)](/filings/0001104659-26-062253.md) | [0.00](/filings/0001104659-26-097216.md) | [0.01](/filings/0001104659-25-112205.md) | not reported | [(0.14)](/filings/0001104659-26-062253.md) | [0.09](/filings/0001104659-26-097216.md) |
| Basic EPS | $ per share | [(0.14)](/filings/0001558370-24-015682.md) | not reported | [0.01](/filings/0001558370-25-007853.md) | [(0.48)](/filings/0001558370-25-011539.md) | [(0.07)](/filings/0001104659-25-112205.md) | not reported | [(0.35)](/filings/0001104659-26-062253.md) | [0.00](/filings/0001104659-26-097216.md) | [0.01](/filings/0001104659-25-112205.md) | not reported | [(0.14)](/filings/0001104659-26-062253.md) | [0.09](/filings/0001104659-26-097216.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [11.3](/filings/0001558370-23-018960.md) | [12.7](/filings/0001558370-25-003976.md) | [10.0](/filings/0001558370-24-008277.md) | [6.9](/filings/0001558370-24-012200.md) | [3.9](/filings/0001558370-24-015682.md) | [4.2](/filings/0001104659-26-036053.md) | [3.4](/filings/0001558370-25-007853.md) | [3.0](/filings/0001558370-25-011539.md) | [3.4](/filings/0001104659-25-112205.md) | [2.6](/filings/0001104659-26-097216.md) | [2.8](/filings/0001104659-26-062253.md) | [2.6](/filings/0001104659-26-097216.md) |
| Current assets | $m | [77.8](/filings/0001558370-23-018960.md) | [77.6](/filings/0001558370-25-003976.md) | [75.7](/filings/0001558370-24-008277.md) | [70.6](/filings/0001558370-24-012200.md) | [68.8](/filings/0001558370-24-015682.md) | [73.3](/filings/0001104659-26-036053.md) | [63.7](/filings/0001558370-25-007853.md) | [63.0](/filings/0001558370-25-011539.md) | [64.1](/filings/0001104659-25-112205.md) | [63.1](/filings/0001104659-26-097216.md) | [60.0](/filings/0001104659-26-062253.md) | [65.9](/filings/0001104659-26-097216.md) |
| Total assets | $m | [182](/filings/0001558370-23-018960.md) | [180](/filings/0001558370-25-003976.md) | [176](/filings/0001558370-24-008277.md) | [161](/filings/0001558370-24-012200.md) | [158](/filings/0001558370-24-015682.md) | [161](/filings/0001104659-26-036053.md) | [149](/filings/0001558370-25-007853.md) | [147](/filings/0001558370-25-011539.md) | [146](/filings/0001104659-25-112205.md) | [143](/filings/0001104659-26-097216.md) | [138](/filings/0001104659-26-062253.md) | [142](/filings/0001104659-26-097216.md) |
| Current liabilities | $m | [9.3](/filings/0001558370-23-018960.md) | [9.4](/filings/0001558370-25-003976.md) | [6.9](/filings/0001558370-24-008277.md) | [7.4](/filings/0001558370-24-012200.md) | [8.0](/filings/0001558370-24-015682.md) | [8.8](/filings/0001104659-26-036053.md) | [9.5](/filings/0001558370-25-007853.md) | [9.0](/filings/0001558370-25-011539.md) | [9.6](/filings/0001104659-25-112205.md) | [9.6](/filings/0001104659-26-097216.md) | [10.4](/filings/0001104659-26-062253.md) | [13.4](/filings/0001104659-26-097216.md) |
| Total liabilities | $m | [82.1](/filings/0001558370-23-018960.md) | [80.4](/filings/0001558370-25-003976.md) | [76.3](/filings/0001558370-24-008277.md) | [75.3](/filings/0001558370-24-012200.md) | [74.4](/filings/0001558370-24-015682.md) | [73.6](/filings/0001104659-26-036053.md) | [72.7](/filings/0001558370-25-007853.md) | [70.6](/filings/0001558370-25-011539.md) | [69.7](/filings/0001104659-25-112205.md) | [68.3](/filings/0001104659-26-097216.md) | [67.5](/filings/0001104659-26-062253.md) | [68.8](/filings/0001104659-26-097216.md) |
| Long-term debt | $m | [1.3](/filings/0001558370-23-018960.md) | [1.2](/filings/0001558370-25-003976.md) | [1.2](/filings/0001558370-24-008277.md) | [1.1](/filings/0001558370-24-012200.md) | [1.0](/filings/0001558370-24-015682.md) | [0.9](/filings/0001104659-25-112205.md) | [0.8](/filings/0001558370-25-007853.md) | [0.7](/filings/0001558370-25-011539.md) | [0.6](/filings/0001104659-25-112205.md) | [0.9](/filings/0001104659-26-036053.md) | not reported | not reported |
| Current portion of debt | $m | [0.3](/filings/0001558370-23-018960.md) | [0.3](/filings/0001558370-25-003976.md) | [0.3](/filings/0001558370-24-008277.md) | [0.3](/filings/0001558370-24-012200.md) | [0.3](/filings/0001558370-24-015682.md) | [0.3](/filings/0001104659-25-112205.md) | [0.3](/filings/0001558370-25-007853.md) | [0.3](/filings/0001558370-25-011539.md) | [0.4](/filings/0001104659-25-112205.md) | not reported | not reported | not reported |
| Shareholders' equity | $m | [99.4](/filings/0001558370-24-015682.md) | [99.3](/filings/0001104659-26-036053.md) | [99.7](/filings/0001558370-25-011539.md) | [85.4](/filings/0001104659-25-112205.md) | [83.5](/filings/0001104659-25-112205.md) | [87.2](/filings/0001104659-26-097216.md) | [76.6](/filings/0001104659-26-097216.md) | [76.5](/filings/0001104659-26-097216.md) | [76.8](/filings/0001104659-25-112205.md) | [74.4](/filings/0001104659-26-097216.md) | [70.1](/filings/0001104659-26-097216.md) | [72.9](/filings/0001104659-26-097216.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent, us-gaap:LongTermDebt
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [7,801 d](/filings/0001558370-24-015682.md) | [1,894 d](/filings/0001104659-26-036053.md) | [(2,022)](/filings/0001558370-25-007853.md) | [(2,703) d](/filings/0001558370-25-011539.md) | [(5,727) d](/filings/0001104659-25-112205.md) | [(1,105) d](/filings/0001104659-26-036053.md) | [(1,475)](/filings/0001104659-26-062253.md) | [(3,734) d](/filings/0001104659-26-097216.md) | [(1,258) d](/filings/0001104659-25-112205.md) | [(597) d](/filings/0001104659-26-036053.md) | [(1,368)](/filings/0001104659-26-062253.md) | [(1,732) d](/filings/0001104659-26-097216.md) |
| Capital expenditure | $k | [143 d](/filings/0001558370-24-015682.md) | [154 d](/filings/0001558370-25-003976.md) | [226](/filings/0001558370-25-007853.md) | [122 d](/filings/0001558370-25-011539.md) | [794 d](/filings/0001104659-25-112205.md) | [298 d](/filings/0001558370-25-003976.md) | [87.0](/filings/0001104659-26-062253.md) | [332 d](/filings/0001104659-26-097216.md) | [89.8 d](/filings/0001104659-25-112205.md) | not reported | [6.2](/filings/0001104659-26-062253.md) | [29.8 d](/filings/0001104659-26-097216.md) |
| Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [33.2](/filings/0001558370-23-018960.md) | [30.0](/filings/0001558370-24-008277.md) | [30.2](/filings/0001558370-24-012200.md) | [29.9](/filings/0001558370-24-015682.md) | [29.9](/filings/0001558370-25-007853.md) | [29.9](/filings/0001558370-25-011539.md) | [29.9](/filings/0001104659-25-112205.md) | [29.9](/filings/0001104659-26-062253.md) | [29.9](/filings/0001104659-26-097216.md) | [29.9](/filings/0001104659-25-112205.md) | [29.9](/filings/0001104659-26-062253.md) | [29.9](/filings/0001104659-26-097216.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 29,937,159 at 2026-08-01, from the cover of the [10-Q filed 2026-08-14](/filings/0001104659-26-097216.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:29 ET. No prices; not investment advice.